RxDoctor Payments Data

Joseph Day

Optometrist · Puyallup, WANPI 1679562433

Payments from drug & device makers

$2,445in general payments, 2019–2025

Across 67 payments — averaging $36.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Mallinckrodt Hospital Products Inc.$677
  • Lumenis BE Inc$575
  • Biotissue Holdings Inc.$284
  • Bausch & Lomb Americas Inc.$219
  • Alcon$131
  • Oyster Point Pharma, Inc.$115
  • plus $444 from 8 others

What the payments were for

  • Food & beverage$2,445100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,445 in reported general payments places this provider in the 85th percentile of 1,267 optometrist providers in Washington.

See all optometrist providers in Washington

Medicare billing

Part B allowed, 2024
$65,095
Medicare patients
261
Services billed
757

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine62$85,804
VyzultaLatanoprostene Bunod39$16,648
Cyclosporine20$15,107
LumiganBimatoprost22$12,285
CombiganBrimonidine Tartrate/Timolol16$7,309
Fluorometholone107$6,958
RhopressaNetarsudil Mesylate12$3,795
Brimonidine Tartrate20$3,543
Travoprost32$2,604
Latanoprost179$2,079
Loteprednol Etabonate17$2,074
Prednisolone Acetate33$1,257
Tobramycin-DexamethasoneTobramycin/Dexamethasone32$1,253
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat110$1,112
ValacyclovirValacyclovir Hcl18$574

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan$111$105,397100 claims
Bausch & Lomb Americas Inc.Vyzulta$219$16,64839 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate$12$2,07417 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,267 optometrist providers in Washington.

Other optometrist in Puyallup

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →